首页> 外文期刊>Urological research >DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder.
【24h】

DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder.

机译:DNA倍性是膀胱肌浸润性移行细胞癌的预后因素。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Radical cystectomy represents the treatment of choice for muscle-infiltrative bladder carcinoma; however, about 50% of patients relapse and die from the disease. In the present study, the prognostic significance of the DNA ploidy in transitional cell carcinoma of the urinary bladder (TCCB) is analyzed. The study was carried out on 66 patients with TCCB who underwent radical cystectomy. DNA ploidy was determined by flow cytometry (FCM) on paraffin-embedded specimens, and the results were analyzed and correlated with the tumor malignancy grade and stage and the clinical course. Forty of the 66 tumors studied (63%) were aneuploid. Aneuploid status was correlated with higher tumor T stage (P < 0.001) and grade (P < 0.001). Median follow up was 68 months (range: 12-105). Median survival was significantly longer in patients with diploid tumors (> 60 vs 45 months, P < 0.001). All patients with diploid tumors were alive and free of bladder cancer during follow-up, in contrast to only 30% of patients with aneuploid tumors. DNA ploidy was an independent prognostic factor, as shown by multivariate analysis (P = 0.006). All patients with pT > or = 3b and diploid tumors were alive at the time of analysis as opposed to none with aneuploid tumors. The results of this study suggest that DNA ploidy can provide prognostic information on patients with muscle invasive carcinoma of the bladder and might represent a means of selection for postoperative management.
机译:根治性膀胱切除术是治疗肌肉浸润性膀胱癌的一种选择。但是,约有50%的患者复发并死于该疾病。在本研究中,分析了DNA倍性在膀胱移行细胞癌(TCCB)中的预后意义。该研究针对66例行根治性膀胱切除术的TCCB患者进行。用流式细胞仪(FCM)对石蜡包埋的标本进行DNA倍性测定,并对结果进行分析,并将其与肿瘤的恶性程度,分期和临床病程相关联。在研究的66种肿瘤中,有40种(63%)是非整倍体。非整倍体状态与较高的肿瘤T分期(P <0.001)和等级(P <0.001)相关。中位随访时间为68个月(范围:12-105)。二倍体肿瘤患者的中位生存期明显更长(> 60 vs 45个月,P <0.001)。在随访期间,所有二倍体肿瘤患者都活着并且没有膀胱癌,而非整倍体肿瘤患者中只有30%。 DNA倍性是一个独立的预后因素,如多因素分析所示(P = 0.006)。在分析时,所有pT>或= 3b且二倍体肿瘤的患者都活着,而非整倍体肿瘤则没有。这项研究的结果表明,DNA倍性可以为膀胱肌肉浸润癌患者提供预后信息,并可能代表术后管理的一种选择手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号